Categories
Biocon Limited — Important, 30-04-2026: Updates
30-04-2026 · 08:27 am
Biocon's Bengaluru biosimilars site completed a U.S. FDA inspection, receiving five procedural observations. These do not pertain to data integrity or quality oversight. The company will submit a corrective action plan, confident all observations will be addressed expeditiously.
No comments yet. Be the first to comment!